- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02398747
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multi-centre study of AZD2014 administered orally in Japanese patients with advanced solid malignancies. The study design allows an evaluation of each cohort with intensive safety monitoring to ensure the safety of the patients. In this study, a minimum of 3 and a maximum of 6 evaluable patients will be enrolled in each cohort; approximately 24 evaluable patients in total. The total number of patients enrolled will depend upon the number of screen failures, number of cohorts and number of evaluable subjects.
Safety, preliminary efficacy and PK (single and multiple dose) are evaluated in this study.
Patients will receive a single dose of AZD2014 on Day 1 (to allow assessment of single dose PK), then after a minimum of 48 hours washout period continuous or intermittent twice daily dosing of AZD2014 will be initiated. The washout period of 48 hours may be extended depending on emerging data from previous cohorts.Doses and schedules to be evaluated will be agreed by AstraZeneca and the Safety Review Committee (SRC).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chuo-ku, Japan, 104-0045
- Research Site
-
Kashiwa, Japan, 277-8577
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological or cytological confirmation of a solid, malignant tumour that is refractory to standard therapies or for which no standard therapies exist
- For Cohort 3-1 and 3-2, followed as, Histological or cytological confirmation of a solid, malignant tumour that is refractory to standard therapies or for which no standard therapies exist or where treatment with paclitaxel is an appropriate treatment option. SqNSCLC patients are excluded from the Cohort 3-2.
- World Health Organisation (WHO) performance status (PS) 0-1 with no deterioration over the previous 2 weeks prior to informed consent and minimum life expectancy of 12 weeks
- At least one lesion that can be accurately assessed at baseline by computed tomography (CT) magnetic resonance imaging (MRI) or plain X-ray and is suitable for repeated assessment
Exclusion Criteria
- Prior chemotherapy, biological therapy, radiation therapy, antiandrogens, other anticancer therapies including immunotherapy and any investigational agents within 21 days of starting study treatment (not including palliative radiotherapy at focal sites), or corticosteroids within 14 days of starting study treatment.
- Major surgery within 4 weeks prior to the study treatment (excluding placement of vascular access), or minor surgery within 2 weeks prior to the study treatment
- Potent or moderate inhibitors or inducers of cytochrome (CYP) 3A4/5 if taken within the stated washout periods:
- Potent or moderate inhibitors or inducers of CYP2C8 if taken within the stated washout periods:
- Exposure to sensitive or narrow therapeutic range substrates of the drug metabolising enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters P-gp (MDR1), Breast cancer resistance protein (BCRP), Organic anion transporting polypeptide (OATP)1B1, OATP1B3, Organic cation transporter (OCT)1 and OCT2 within the appropriate wash-out period (at least 5 x reported terminal elimination half-life (t1/2) of each drug) before the study treatment.
- Any haemopoietic growth factors (eg, granulocyte-colony stimulating factor [G-CSF]) within 2 weeks prior to receiving study drug
- Previous initiation of treatment with AZD2014 in the present study or prior treatment with AZD8055
- With the exception of alopecia, any unresolved toxicities from prior chemotherapy greater than Common toxicity criteria for adverse events (CTCAE) grade 1 at the time of starting study treatment
- Spinal cord or brain metastases unless asymptomatic and stable off steroids for at least 4 weeks prior to start of study treatment
- Subjects with interstitial lung disease as a complication or a history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD2014 50mg, 125mg, 25mg and 50mg intermittent BD
50mg BD continuous dosing, 125mg BD intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
|
50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability measured by adverse events
Time Frame: 6 months in average
|
This will be assessed in terms of Adverse Events (AEs), laboratory data, vital signs, ECG and physical exams
|
6 months in average
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of AZd2014
Time Frame: 21 days
|
Characterising the pharmacokinetics (PK) of AZD2014
|
21 days
|
AUC(Area under the plasma concentration-time curve) of AZD2014
Time Frame: 21 days
|
Characterising the pharmacokinetics (PK) of AZD2014
|
21 days
|
Tmax of AZD2014
Time Frame: 21 days
|
Characterising the pharmacokinetics (PK) of AZD2014
|
21 days
|
To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Time Frame: 6 months in average
|
Best overall response
|
6 months in average
|
To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Time Frame: 6 months in average
|
Objective response rate
|
6 months in average
|
To obtain a preliminary assessment of the anti-tumour activity of AZD2014 by evaluation of tumour response using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Time Frame: 6 months in average
|
Percentage change in tumour size
|
6 months in average
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D2270C00008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Malignancies
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnMetastatic Solid Malignancies | Locally Advanced Solid MalignanciesCanada
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
AstraZenecaActive, not recruitingAdvanced Solid MalignanciesJapan
-
AstraZenecaActive, not recruitingAdvanced Solid MalignanciesRomania, Moldova, Republic of
-
Novartis PharmaceuticalsCompletedAdvanced Solid MalignanciesNetherlands
-
Samyang Biopharmaceuticals CorporationCompleted
-
AstraZenecaCompletedAdvanced Solid MalignanciesUnited Kingdom
-
Regeneron PharmaceuticalsSanofiCompletedAdvanced Solid MalignanciesUnited States
Clinical Trials on AZD2014
-
Samsung Medical CenterWithdrawn
-
Massachusetts General HospitalUnited States Department of Defense; AstraZenecaCompletedMeningioma | Neurofibromatosis 2United States
-
Massachusetts General HospitalNational Cancer Institute (NCI); AstraZenecaActive, not recruiting
-
Samsung Medical CenterAstraZenecaTerminatedSmall Cell Lung CancerKorea, Republic of
-
Samsung Medical CenterWithdrawnSolid TumorKorea, Republic of
-
AstraZenecaWithdrawnCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompletedAdvanced CancerUnited Kingdom
-
Canadian Cancer Trials GroupAstraZenecaCompletedGlioblastoma MultiformeCanada
-
Samsung Medical CenterTerminatedCancer of StomachKorea, Republic of
-
Samsung Medical CenterTerminatedStomach NeoplasmsKorea, Republic of